LATHAM, N.Y.–(BUSINESS WIRE)–Sep. 15, 2021– AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular…
Read More
AngioDynamics, with its disruptive and innovative medical devices, addresses unmet patient needs by elevating the standard of care for chronic and acute disease states in vascular, peripheral vascular, and oncology medicine.
These devices provide healthcare professionals around the world with the vital tools they need to deliver high-quality patient care and improve patient outcomes.
“The acquisition of Auryon brings a remarkable, foundational technology to our portfolio that will change the way caregivers deliver treatment…
The BioFlo PICC is the first PICC of its kind with Endexo Technology, providing a catheter more resistant to the…
The Solero* Microwave Tissue Ablation (MTA) System and Accessories are indicated for the ablation of soft tissue during open procedures….
It takes a team of talented people to become one of the world’s leading providers of innovative medical devices.
The deep commitment and contributions of our employees helped to build a global company that’s pioneering new ways to improve patient outcomes.
If you find the idea of joining a dynamic team that’s dedicated to improving the lives of patients appealing, we invite you to review our available opportunities.
If you weren't able to engage (virtually) with our Vascular Access team during the @ISaveThatLine 2021 Scientific Meeting, please visit http://ow.ly/Ja9850GdjkI to connect with the AngioDynamic representative serving your region.
#AVASM21 #vascularaccess #meddevice
Will we see you tonight for this discussion with Dr. Ayman Farid? REGISTER NOW to learn the role cardiologists play in treating veins and how you can start a venous program in your cardiology practice: https://www.eventbrite.com/e/the-role-of-the-cardiologist-in-treating-veins-registration-167378502607
https://bit.ly/VCEVLTRiskInfo #EVLT #CardioTwitter
Our clinical study – PRESERVE – is working to improve treatment options for patients with prostate cancer. Learn more about the study at .
PRESERVE - AngioDynamics
PRESERVE: Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population This study, initiated...
AngioPRESERVE.com
Looking forward to discussing our leading vascular access technology and devices with virtual attendees of @ISaveThatLine's 2021 Scientific Meeting. Will we (virtually) see you there?
#avasm21 #vascularaccess
AngioDynamics® history is best characterized by innovation and growth. Originally founded in Queensbury, N.Y., U.S., in 1988, AngioDynamics has grown into a NASDAQ-listed public company with a global reach.
Latham, NY (HQ)
Glens Falls, NY (Manufacturing)
Queensbury, NY (Manufacturing)
Marlborough, MA (R&D)
Amsterdam, NL (International HQ)
São Paulo, BR (Brazil Office)
Oakville, CA (Canada Office)
Hong Kong, HK (Asia Pacific Regional Office)
Rehovot, IL (Israel Office)
